This post was originally published on this site Regeneron‘s bispecific antibody REGN1979 is showing outstanding clinical effectiveness in B-cell non-Hodgkin’s lymphoma patients who received prior treatments, including those who progressed after CAR T-cell therapies. The treatment completely eliminated the cancer in 71% of follicular lymphoma and 57% of diffuse large B-cell lymphoma patients participated in…
About Cancer
Cancer, also called malignancy, is an abnormal growth of cells with the potential to invade or spread to surrounding tissues and structures found within the body. There are more than 100 types of cancer. A few examples include breast cancer, skin cancer, lung cancer, colon cancer, prostate cancer, and lymphoma. According to the American Cancer Society, 4 out of 10 people will be diagnosed with some form of cancer in their lifetime. Cancer prevalence has given rise to multiple medical specialties focused on symptom management and disease management. Current treatment options depending on the form of cancer include chemotherapy, radiation, blood or bone marrow transfusions, and/or surgery. Lifetime prognosis of cancer mortality is dependent on the type of cancer and is heavily conditional to early detection.
Conditions
Cancer News
Cancer Vaccine VBI-1901 Well-Tolerated in Recurrent Glioblastoma Patients, Early Phase 1/2a Data Show
This post was originally published on this site Treatment of recurrent glioblastoma with the investigational cancer vaccine VBI-1901 was well-tolerated and associated with stable disease in a subset of patients, according to findings of a Phase 1/2a trial. The study, “Interim results of a phase I/IIa trial of a therapeutic CMV vaccine against recurrent glioblastoma…
68Ga-PSMA-11 Better than Axumin at Detecting PC Recurrence, Trial Shows
This post was originally published on this site Among men suspected of having prostate cancer recurrence after surgery, the radiotracer 68Ga-PSMA-11 is better at detecting the cancerous lesions and provides better agreement among experts than the standard Axumin (18F-fluciclovine) tracer, a Phase 2 trial shows. The results were presented at the 2019 Society of Nuclear…
Lynparza Approved in Japan as First-Line Maintenance Therapy for Advanced OC
This post was originally published on this site Lynparza (olaparib) has been approved in Japan as a first-line maintenance treatment for women with BRCA-mutated advanced ovarian cancer that is responding, partially or completely, to their initial chemotherapy, AstraZeneca and Merck (known as MSD outside the U.S. and Canada) announced. Similar approvals have previously been granted in the U.S.,…
FDA Approves Xpovio Combo for Heavily Treated RRMM Patients
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has approved — with conditions — Xpovio (selinexor) tablets, in combination with the corticosteroid dexamethasone, for the treatment of adults with relapsed or refractory multiple myeloma who received at least four prior therapies and failed to respond to treatment. The…
Workplace Hazards Account for 30% of Sarcoidosis Cases, Study Suggests
This post was originally published on this site Work-related hazards account for nearly 1 in 3 cases of sarcoidosis, and for at least 1 in 10 cases of other respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), and bronchitis, a new analysis suggests. The analyss, “The Occupational Burden of Nonmalignant Respiratory Diseases. An Official…
Puma Applies to FDA to Extend Nerlynx’s Use to HER2-Positive Metastatic Breast Cancer
This post was originally published on this site Puma Biotechnology is seeking to extend the use of its breast cancer medicine Nerlynx (neratinib), in combination with capecitabine, to treat women with HER2-positive breast cancer whose disease has spread to other parts of the body, and is metastatic. In a supplemental New Drug Application (sNDA) filed…
World’s First Alport Stamp Is Macedonian Mom’s Latest Win for Rare Disease Patients
This post was originally published on this site It wasn’t until Gordana Loleska’s son David was 14 years old that doctors in their native North Macedonia diagnosed his kidney, vision, and hearing problems as Alport syndrome. Although she had known for years that something was wrong, the news that David would battle a lifelong rare…
Adding Xtandi to Xofigo Does Not Raise Risk of Bone Issues in CRPC, Study Says
This post was originally published on this site Metastatic castration-resistant prostate cancer (CRPC) patients who receive Xtandi (enzalutamide) plus Xofigo (radium-223) in a real-world setting do not experience more fractures or bone-related events than those given Xofigo alone, an observational study shows. This has been a common concern for metastatic CRPC patients, among whom Xofigo…
New Blood Test May Improve Ovarian Cancer Diagnosis, Study Suggests
This post was originally published on this site A blood test that examines a panel of 11 specific proteins could help distinguish between benign tumors and malignant ovarian cancer, reducing the need for unnecessary surgeries and leading to an earlier diagnosis, a study shows. Conducted by researchers at Uppsala University and Sahlgrenska Academy at the…
Scientists Find ‘On/off Switch’ of Malignant MM Cancer Cells, May Lead to New Therapies, Study Says
This post was originally published on this site Scientists discovered a set of genes that work as an “on/off switch” for malignant multiple myeloma cancer cells, which may shed light into new therapeutic targets for the disease, and for other types of cancers with a higher tendency to spread to bones. The findings of the…
Imfinzi Combo Therapy Extends Survival of Advanced SCLC Patients, Phase 3 Trial Shows
This post was originally published on this site Adding Imfinzi (durvalumab) to standard first-line chemotherapy led to a clinically meaningful extension in the overall survival of patients with advanced small cell lung cancer (SCLC), according to results of a Phase 3 clinical trial. The open-label, global CASPIAN trial (NCT03043872) is testing AstraZeneca’s Imfinzi combined with…